| 摘要 |
<p num="1"><br/><br/><br/>The present invention provides methods for determining a level of methotrexate <br/>polyglutamates (MTXPGs) in an individual undergoing methotrexate (MTX) therapy <br/>and for optimizing dose efficacy of MTX therapy in an individual by genotyping <br/>the individual at a polymorphic site in at least one folate pathway gene <br/>(e.g., a reduced folate carrier (RFC-1) gene, a gamma glutamyl hydrolase (GGH) <br/>gene, etc.). Methods are also provided for determining a level of MTXPGs in an <br/>individual undergoing MTX therapy and for optimizing dose efficacy of MTX <br/>therapy in an individual by generating a pharmacogenetic index based upon the <br/>genotype of the individual at a polymorphic site in an RFC-1 gene and/or a GGH <br/>gene.<br/>
|
